Published in Immunol Rev on November 01, 2011
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med (2016) 2.16
Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma. J Immunother Cancer (2016) 1.41
Cancer immunotherapy: the beginning of the end of cancer? BMC Med (2016) 1.32
Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype. J Exp Med (2012) 1.32
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Modulation of GITR for cancer immunotherapy. Curr Opin Immunol (2012) 1.17
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
Inherited human OX40 deficiency underlying classic Kaposi sarcoma of childhood. J Exp Med (2013) 1.14
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy. ISRN Oncol (2013) 1.04
CD40 ligation reverses T cell tolerance in acute myeloid leukemia. J Clin Invest (2013) 1.04
Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade. Expert Rev Anticancer Ther (2012) 1.03
GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability. Cancer Immunol Res (2013) 1.02
Delta-24-RGD oncolytic adenovirus elicits anti-glioma immunity in an immunocompetent mouse model. PLoS One (2014) 1.02
Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma. J Immunother Cancer (2015) 0.95
Improved mouse models to assess tumour immunity and irAEs after combination cancer immunotherapies. Clin Transl Immunology (2014) 0.95
Novel antibodies targeting immune regulatory checkpoints for cancer therapy. Br J Clin Pharmacol (2013) 0.94
Abnormal interactions between perifollicular mast cells and CD8+ T-cells may contribute to the pathogenesis of alopecia areata. PLoS One (2014) 0.92
Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer (2014) 0.87
Age-dependent divergent effects of OX40L treatment on the development of diabetes in NOD mice. Autoimmunity (2016) 0.86
SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines. Expert Rev Vaccines (2014) 0.85
Identification and characterization of an agonistic aptamer against the T cell costimulatory receptor, OX40. Nucleic Acid Ther (2012) 0.85
CD134/CD137 dual costimulation-elicited IFN-γ maximizes effector T-cell function but limits Treg expansion. Immunol Cell Biol (2013) 0.84
T cell costimulation by TNFR superfamily (TNFRSF)4 and TNFRSF25 in the context of vaccination. J Immunol (2012) 0.84
Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology (2013) 0.82
Turning T cells on: epigenetically enhanced expression of effector T-cell costimulatory molecules on irradiated human tumor cells. J Immunother Cancer (2013) 0.81
OX40 controls effector CD4+ T-cell expansion, not follicular T helper cell generation in acute Listeria infection. Eur J Immunol (2014) 0.80
Intratumoral CD4+ T lymphodepletion sensitizes poorly immunogenic melanomas to immunotherapy with an OX40 agonist. J Invest Dermatol (2014) 0.80
The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. PLoS One (2013) 0.79
New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin Cancer Res (2015) 0.78
Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein-protein interaction. Br J Pharmacol (2014) 0.77
TNF superfamily protein-protein interactions: feasibility of small- molecule modulation. Curr Drug Targets (2015) 0.77
Three steps to breaking immune tolerance to lymphoma: a microparticle approach. Cancer Immunol Res (2015) 0.77
Immune checkpoint inhibitor combinations in solid tumors: opportunities and challenges. Immunotherapy (2016) 0.77
OX40 ligand expressed in glioblastoma modulates adaptive immunity depending on the microenvironment: a clue for successful immunotherapy. Mol Cancer (2015) 0.77
OX40 expression enhances the prognostic significance of CD8 positive lymphocyte infiltration in colorectal cancer. Oncotarget (2015) 0.76
Melanoma immunotherapy. Cancer Biol Ther (2014) 0.76
Strategies to overcome the hurdles to treat fibrosis, a major unmet clinical need. Proc Natl Acad Sci U S A (2016) 0.75
Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy. J Immunol (2015) 0.75
T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management. Immunotargets Ther (2013) 0.75
Effector function of CTLs is increased by irradiated colorectal tumor cells that modulate OX-40L and 4-1BBL and is reversed following dual blockade. BMC Res Notes (2016) 0.75
Intravesical BCG induces CD4(+) T-Cell Expansion in an Immune Competent Model of Bladder Cancer. Cancer Immunol Res (2017) 0.75
Signals that drive T follicular helper cell formation. Immunology (2017) 0.75
Cytokines and metabolic factors regulate tumoricidal T-cell function during cancer immunotherapy. Immunotherapy (2017) 0.75
Molecular mechanisms underlying Th1-like Treg generation and function. Cell Mol Life Sci (2017) 0.75
The Ox40/Ox40 Ligand Pathway Promotes Pathogenic Th Cell Responses, Plasmablast Accumulation, and Lupus Nephritis in NZB/W F1 Mice. J Immunol (2017) 0.75
Optimal CD4 T cell priming after LPS-based adjuvanticity with CD134 costimulation relies on CXCL9 production. J Leukoc Biol (2017) 0.75
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 19.77
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med (2011) 18.99
Enhancement of antitumor immunity by CTLA-4 blockade. Science (1996) 17.94
IL-4 directs the development of Th2-like helper effectors. J Immunol (1990) 7.20
Development and homeostasis of T cell memory in rhesus macaque. J Immunol (2002) 6.88
Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer (2007) 5.65
Identification of a human OX-40 ligand, a costimulator of CD4+ T cells with homology to tumor necrosis factor. J Exp Med (1994) 5.60
Immunological aspects of demyelinating diseases. Annu Rev Immunol (1992) 4.39
Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med (1997) 3.89
Insufficient production and tissue delivery of CD4+ memory T cells in rapidly progressive simian immunodeficiency virus infection. J Exp Med (2004) 3.62
Antigens of activated rat T lymphocytes including a molecule of 50,000 Mr detected only on CD4 positive T blasts. Mol Immunol (1987) 3.36
Control of immunity by the TNFR-related molecule OX40 (CD134). Annu Rev Immunol (2010) 2.67
Anti-TIM3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumors. Cancer Res (2011) 2.59
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC. Nat Rev Clin Oncol (2009) 2.48
CD4 T cell cytokine differentiation: the B cell activation molecule, OX40 ligand, instructs CD4 T cells to express interleukin 4 and upregulates expression of the chemokine receptor, Blr-1. J Exp Med (1998) 2.45
IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J Clin Invest (2006) 2.41
Triggering of OX40 (CD134) on CD4(+)CD25+ T cells blocks their inhibitory activity: a novel regulatory role for OX40 and its comparison with GITR. Blood (2004) 2.38
Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol (2010) 2.24
Characterization of the MRC OX40 antigen of activated CD4 positive T lymphocytes--a molecule related to nerve growth factor receptor. EMBO J (1990) 2.21
Cross-linking of OX40 ligand, a member of the TNF/NGF cytokine family, induces proliferation and differentiation in murine splenic B cells. Immunity (1995) 2.17
Transforming growth factor-beta and IL-4 cause helper T cell precursors to develop into distinct effector helper cells that differ in lymphokine secretion pattern and cell surface phenotype. J Immunol (1991) 2.15
Adoptive T cell therapy of cancer. Curr Opin Immunol (2010) 2.13
Expression and function of OX40 ligand on human dendritic cells. J Immunol (1997) 2.13
Therapeutic targeting of the effector T-cell co-stimulatory molecule OX40. Nat Rev Immunol (2004) 2.12
CD4+ T cell subsets. Lymphokine secretion of memory cells and of effector cells that develop from precursors in vitro. J Immunol (1990) 2.08
Multiple roles for CD4+ T cells in anti-tumor immune responses. Immunol Rev (2008) 2.07
Ox40-ligand has a critical costimulatory role in dendritic cell:T cell interactions. Immunity (1999) 2.02
CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol (2001) 1.82
Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol (2011) 1.80
Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol (2000) 1.74
Distinct regulation of lymphokine production is found in fresh versus in vitro primed murine helper T cells. J Immunol (1990) 1.73
T-cell modulation combined with intratumoral CpG cures lymphoma in a mouse model without the need for chemotherapy. Blood (2008) 1.69
Blocking OX-40/OX-40 ligand interaction in vitro and in vivo leads to decreased T cell function and amelioration of experimental allergic encephalomyelitis. J Immunol (1999) 1.69
Contribution of OX40/OX40 ligand interaction to the pathogenesis of rheumatoid arthritis. Eur J Immunol (2000) 1.65
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. J Exp Med (2009) 1.63
OX40 is required for regulatory T cell-mediated control of colitis. J Exp Med (2010) 1.62
Clinical effects and toxicity of interleukin-2 in patients with cancer. Cancer (1986) 1.60
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Toll-like receptor agonists in cancer therapy. Immunotherapy (2009) 1.58
Molecular characterization of murine and human OX40/OX40 ligand systems: identification of a human OX40 ligand as the HTLV-1-regulated protein gp34. EMBO J (1994) 1.52
OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Res (2008) 1.51
Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth. Cancer Res (2000) 1.46
Danger and OX40 receptor signaling synergize to enhance memory T cell survival by inhibiting peripheral deletion. J Immunol (2000) 1.45
The crystal structure of the costimulatory OX40-OX40L complex. Structure (2006) 1.44
OX-40: life beyond the effector T cell stage. Semin Immunol (1998) 1.43
A new superfamily of cell surface proteins related to the nerve growth factor receptor. Immunol Today (1991) 1.37
Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy. J Immunother (2010) 1.37
OX40 drives protective vaccinia virus-specific CD8 T cells. J Immunol (2008) 1.33
Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. J Immunol (2009) 1.32
OX40 costimulation promotes persistence of cytomegalovirus-specific CD8 T Cells: A CD4-dependent mechanism. J Immunol (2007) 1.26
Selective depletion of myelin-reactive T cells with the anti-OX-40 antibody ameliorates autoimmune encephalomyelitis. Nat Med (1996) 1.25
Manipulation of costimulatory signals to enhance antitumor T-cell responses. Curr Opin Immunol (1995) 1.25
Defects in the acquisition of CD8 T cell effector function after priming with tumor or soluble antigen can be overcome by the addition of an OX40 agonist. J Immunol (2007) 1.24
The TNFR family members OX40 and CD27 link viral virulence to protective T cell vaccines in mice. J Clin Invest (2010) 1.24
Engagement of OX40 enhances antigen-specific CD4(+) T cell mobilization/memory development and humoral immunity: comparison of alphaOX-40 with alphaCTLA-4. J Immunol (2001) 1.23
A glycoprotein antigen detected with new monoclonal antibodies on the surface of human lymphocytes infected with human T-cell leukemia virus type-I (HTLV-I). Int J Cancer (1985) 1.23
4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J Immunol (2011) 1.20
OX40: targeted immunotherapy--implications for tempering autoimmunity and enhancing vaccines. Trends Immunol (2002) 1.20
Constitutive OX40/OX40 ligand interaction induces autoimmune-like diseases. J Immunol (2002) 1.20
Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor. J Immunol (2001) 1.19
Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses. Eur J Immunol (2007) 1.18
4-1BB and OX40 dual costimulation synergistically stimulate primary specific CD8 T cells for robust effector function. J Immunol (2004) 1.16
Impact of tumour volume on the potential efficacy of therapeutic vaccines. Curr Oncol (2011) 1.15
IL-12 is required for anti-OX40-mediated CD4 T cell survival. J Immunol (2008) 1.14
OX40 costimulatory signals potentiate the memory commitment of effector CD8+ T cells. J Immunol (2008) 1.12
Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother (2010) 1.10
Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol (2001) 1.09
OX40-mediated memory T cell generation is TNF receptor-associated factor 2 dependent. J Immunol (2003) 1.06
Cytokines in neuroinflammatory disease: role of myelin autoreactive T cell production of interferon-gamma. J Neuroimmunol (1992) 1.04
Ligation of OX40 (CD134) regulates graft-versus-host disease (GVHD) and graft rejection in allogeneic bone marrow transplant recipients. Blood (2003) 1.03
Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph node cells from patients with melanoma and head and neck cancers. Am J Surg (1997) 1.03
Immune reactivity in the nervous system: modulation of T-lymphocyte activation by glial cells. J Exp Biol (1987) 1.03
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Ligation of the OX40 co-stimulatory receptor reverses self-Ag and tumor-induced CD8 T-cell anergy in vivo. Eur J Immunol (2009) 1.03
Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother (2006) 1.01
Targeting OX40 and OX40L for the treatment of autoimmunity and cancer. Crit Rev Immunol (2007) 1.00
Involvement of OX40-OX40L interactions in the intestinal manifestations of the murine acute graft-versus-host disease. Gastroenterology (1998) 0.98
Functional expression of CD134 by neutrophils. Eur J Immunol (2004) 0.98
Transforming growth factor-beta enhances the in vivo effector function and memory phenotype of antigen-specific T helper cells in experimental autoimmune encephalomyelitis. J Immunol (1992) 0.96
Self-antigen prevents CD8 T cell effector differentiation by CD134 and CD137 dual costimulation. J Immunol (2008) 0.93
Where, when, and how to detect biased expression of disease-relevant V beta genes in rats with experimental autoimmune encephalomyelitis. J Immunol (1993) 0.92
Targeting OX40 promotes lung-resident memory CD8 T cell populations that protect against respiratory poxvirus infection. J Virol (2011) 0.92
The role of macrophages in demyelination. J Neuroimmunol (1992) 0.89
First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials. Am J Ther (2007) 0.89
OX40 ligand regulates inflammation and mortality in the innate immune response to sepsis. J Immunol (2010) 0.87
History of antibody therapy for non-Hodgkin's lymphoma. Semin Oncol (2003) 0.86
Immune effects of trastuzumab. J Cancer (2011) 0.84
Analysis of T cell receptor beta chains in Lewis rats with experimental allergic encephalomyelitis: conserved complementarity determining region 3. J Exp Med (1991) 0.83
Synergistic OX40 and CD30 signals sustain CD8+ T cells during antigenic challenge. Eur J Immunol (2009) 0.82
Pre-treatment with cyclophosphamide or OX40 (CD134) costimulation targeting regulatory T cell function enhances the anti-tumor immune effect of adoptively transferred CD8+ T cells from wild-type mice. Mol Med Rep (2011) 0.79
Lymphokine mRNA expression in the spinal cords of Lewis rats with experimental autoimmune encephalomyelitis is associated with a host recruited CD45R hi/CD4+ population during recovery. J Neuroimmunol (1993) 0.79
Sipuleucel-T in patients with metastatic castration-resistant prostate cancer: an insight for oncologists. Ther Adv Med Oncol (2011) 0.77
V beta CDR3 motifs associated with BP recognition are enriched in OX-40+ spinal cord T cells of Lewis rats with EAE. J Neurosci Res (1996) 0.76
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Sunitinib in patients with metastatic renal cell carcinoma. JAMA (2006) 11.33
Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol (2005) 4.64
Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 3.67
Sunitinib efficacy against advanced renal cell carcinoma. J Urol (2007) 3.14
Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma. J Clin Oncol (2008) 2.77
Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol Cell Biol (2003) 2.50
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Efficient cross-presentation depends on autophagy in tumor cells. Cancer Res (2008) 2.05
Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci (2013) 2.03
Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res (2002) 1.89
Granulocyte macrophage colony-stimulating factor--secreting allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res (2007) 1.71
Phase 1 study of stereotactic body radiotherapy and interleukin-2--tumor and immunological responses. Sci Transl Med (2012) 1.61
Phase I study of recombinant interleukin-21 in patients with metastatic melanoma and renal cell carcinoma. J Clin Oncol (2008) 1.60
Bovine apolipoprotein B-100 is a dominant immunogen in therapeutic cell populations cultured in fetal calf serum in mice and humans. Blood (2007) 1.52
Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol (2003) 1.50
Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol (2003) 1.49
A phase II study of bevacizumab and high-dose interleukin-2 in patients with metastatic renal cell carcinoma: a Cytokine Working Group (CWG) study. J Immunother (2013) 1.48
Are all hypotheses generated before data analysis prospective? J Clin Oncol (2002) 1.38
Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma. J Clin Oncol (2007) 1.37
Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res (2005) 1.36
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment. J Transl Med (2013) 1.31
Tumor-derived autophagosome vaccine: mechanism of cross-presentation and therapeutic efficacy. Clin Cancer Res (2011) 1.30
Signaling through OX40 enhances antitumor immunity. Semin Oncol (2010) 1.27
HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I. Cell Host Microbe (2007) 1.26
Adjuvant immunization of HLA-A2-positive melanoma patients with a modified gp100 peptide induces peptide-specific CD8+ T-cell responses. J Clin Oncol (2003) 1.17
Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther (2003) 1.17
The TNFRs OX40, 4-1BB, and CD40 as targets for cancer immunotherapy. Curr Opin Immunol (2013) 1.16
Combination chemotherapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res (2008) 1.12
Cross-presentation of tumor associated antigens through tumor-derived autophagosomes. Autophagy (2009) 1.10
gp100(209-2M) peptide immunization of human lymphocyte antigen-A2+ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8+ T cells. Clin Cancer Res (2004) 1.08
Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer (2009) 1.04
Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain. Mol Immunol (2007) 1.03
Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data. Cytometry A (2006) 1.03
Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med (2006) 1.02
Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res (2008) 1.02
Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study. J Immunother (2006) 1.01
TNF plays an essential role in tumor regression after adoptive transfer of perforin/IFN-gamma double knockout effector T cells. J Immunol (2003) 1.00
Active-specific immunotherapy for non-small cell lung cancer. J Thorac Dis (2011) 0.99
Autophagy-assisted antigen cross-presentation: Autophagosome as the argo of shared tumor-specific antigens and DAMPs. Oncoimmunology (2012) 0.94
Cancer immunotherapy: the role regulatory T cells play and what can be done to overcome their inhibitory effects. Curr Mol Med (2009) 0.91
Induction of circulating tumor-reactive CD8+ T cells after vaccination of melanoma patients with the gp100 209-2M peptide. J Immunother (2007) 0.91
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology (2010) 0.91
CD28, TNF receptor, and IL-12 are critical for CD4-independent cross-priming of therapeutic antitumor CD8+ T cells. J Immunol (2002) 0.91
Defining a functionally distinct subset of human memory CD4+ T cells that are CD25POS and FOXP3NEG. Eur J Immunol (2012) 0.91
Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J Immunother (2006) 0.91
Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother (2003) 0.89
Regression of a mammary adenocarcinoma in STAT6-/- mice is dependent on the presence of STAT6-reactive T cells. J Immunol (2003) 0.89
Adoptive cellular therapy with tumor vaccine draining lymph node lymphocytes after vaccination with HLA-B7/beta2-microglobulin gene-modified autologous tumor cells. J Immunother (2002) 0.86
Redirecting T cells. N Engl J Med (2011) 0.85
Integrating new therapies in the treatment of advanced melanoma. Curr Treat Options Oncol (2012) 0.84
CD122+CD8+ Treg suppress vaccine-induced antitumor immune responses in lymphodepleted mice. Eur J Immunol (2010) 0.84
Cross-presentation of viral antigens in dribbles leads to efficient activation of virus-specific human memory T cells. J Transl Med (2014) 0.83
Multiple vaccinations: friend or foe. Cancer J (2011) 0.83
The iSBTc/SITC primer on tumor immunology and biological therapy of cancer: a summary of the 2010 program. J Transl Med (2011) 0.82
Allogeneic breast cancer cell vaccines. Clin Breast Cancer (2003) 0.81
Immunotherapy for melanoma: the good, the bad, and the future. Curr Oncol Rep (2005) 0.81
Characterization of the class I-restricted gp100 melanoma peptide-stimulated primary immune response in tumor-free vaccine-draining lymph nodes and peripheral blood. Clin Cancer Res (2009) 0.80
Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells. Clin Exp Metastasis (2004) 0.78
Reduced L-selectin (CD62LLow) expression identifies tumor-specific type 1 T cells from lymph nodes draining an autologous tumor cell vaccine. Cell Immunol (2004) 0.78
Altered chemokine receptor sensitivity in FVBN202 rat neu transgenic mice. Breast Cancer Res Treat (2003) 0.78
CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in multiple myeloma. Hum Vaccin Immunother (2015) 0.76
An open-label, phase 2 trial of RPI.4610 (Angiozyme) in the treatment of metastatic breast cancer. Cancer (2012) 0.75
Phase I/II trial of outpatient PEG-interferon with interleukin-2 in advanced renal cell carcinoma: a cytokine working group study. J Immunother (2007) 0.75
Undefined-antigen vaccines. Cancer Treat Res (2005) 0.75
Immunological monitoring of patients with melanoma after peptide vaccination using soluble peptide/HLA-A2 dimer complexes. J Immunother (2003) 0.75